{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:08:36Z","timestamp":1783634916169,"version":"3.55.0"},"reference-count":23,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Background: Non-alcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of metabolic syndrome. Recently, the term metabolic dysfunction-associated fatty liver disease (MAFLD) has been proposed and adapted to body mass index (BMI). This study describes the impact on prevalence of the application of both criteria in overweight and lean patients. Methods: Patients who were evaluated for liver steatosis by transient elastography were included and divided according to BMI (\u226525 kg\/m2 and &lt;25 kg\/m2) and classified as NAFLD or MAFLD, according to metabolic abnormalities. Differences in prevalence were evaluated applying both criteria. A multivariate analysis was performed to evaluate independent associations of metabolic abnormalities and liver steatosis in lean patients. Results: 3847 patients were included. In overweight patients (61%), the prevalence NAFLD was 63.6% and 65.3% for MAFLD (p = 0.22). In contrast, the prevalence of MAFLD was lower (7.9% vs. 18.3%, p \u2264 0.001) in lean patients. In this group, higher age, fasting glucose, triglycerides, and waist circumference showed independent association with liver steatosis. Conclusion: The application of NAFLD\/MAFLD criteria did not show prevalence differences in overweight patients. With MAFLD criteria, the prevalence is lower in lean patients, but patients with high risk of progression of liver disease for steatosis were identified, according to their metabolic abnormalities.<\/jats:p>","DOI":"10.3390\/ijerph191912221","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T23:12:12Z","timestamp":1664320332000},"page":"12221","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Impact on Prevalence of the Application of NAFLD\/MAFLD Criteria in Overweight and Normal Weight Patients"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0358-5975","authenticated-orcid":false,"given":"Ana Luisa","family":"Ordo\u00f1ez-V\u00e1zquez","sequence":"first","affiliation":[{"name":"Gastroenterology and Obesity Unit, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1756-7268","authenticated-orcid":false,"given":"Eva","family":"Ju\u00e1rez-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Translational Research Unit, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Mar\u00eda","family":"Zuarth-V\u00e1zquez","sequence":"additional","affiliation":[{"name":"Internal Medicine Unit, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha Helena","family":"Ramos-Ostos","sequence":"additional","affiliation":[{"name":"Diagnosis and Treatment Unit, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misael","family":"Uribe","sequence":"additional","affiliation":[{"name":"Gastroenterology and Obesity Unit, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7511-5396","authenticated-orcid":false,"given":"Graciela","family":"Castro-Narro","sequence":"additional","affiliation":[{"name":"Transplants and Hepatology Unit, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"L\u00f3pez-M\u00e9ndez","sequence":"additional","affiliation":[{"name":"Transplants and Hepatology Unit, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease","volume":"64","author":"Marchesini","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00423-020-01965-1","article-title":"Mechanisms of Nonalcoholic Fatty Liver Disease and Implications for Surgery","volume":"406","author":"Kaufmann","year":"2021","journal-title":"Langenbeck\u2019s Arch. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1210\/er.2019-00034","article-title":"The Liver as an Endocrine Organ\u2014Linking NAFLD and Insulin Resistance","volume":"40","author":"Watt","year":"2019","journal-title":"Endocr. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Chen, J., and Vitetta, L. (2020). Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155214"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-981-10-8684-7_9","article-title":"Microbiota, Obesity and NAFLD","volume":"1061","author":"Lau","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_6","first-page":"169","article-title":"The Gut Microbiome, Diet, and Links to Cardiometabolic and Chronic Disorders","volume":"123","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.dsx.2020.09.026","article-title":"Pathophysiological Mechanisms Underlying MAFLD","volume":"14","author":"Kuchay","year":"2020","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/HMER.S188991","article-title":"A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis","volume":"11","author":"Ganguli","year":"2019","journal-title":"Hepat. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.3748\/wjg.v24.i19.2083","article-title":"Mediterranean Diet and Nonalcoholic Fatty Liver Disease","volume":"24","author":"Anania","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Torres, M.C.P., Aghemo, A., Lleo, A., Bodini, G., Furnari, M., Marabotto, E., Miele, L., and Giannini, E.G. (2019). Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered. Nutrients, 11.","DOI":"10.3390\/nu11122971"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jhep.2021.08.020","article-title":"Prognosis of MAFLD vs. NAFLD and Implications for a Nomenclature Change","volume":"75","author":"Wong","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_13","first-page":"1236","article-title":"Risk Factors of Nonalcoholic Fatty Liver Disease in Lean Body Mass Population: A Systematic Review and Meta-Analysis","volume":"5","author":"Alam","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.30908","article-title":"Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation","volume":"71","author":"Chen","year":"2020","journal-title":"Hepatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global Prevalence, Incidence, and Outcomes of Non-Obese or Lean Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.cgh.2020.10.046","article-title":"Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease","volume":"19","author":"Wong","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6662760","DOI":"10.1155\/2021\/6662760","article-title":"Controlled Attenuation Parameter for Quantification of Steatosis: Which Cut-Offs to Use?","volume":"2021","author":"Sirli","year":"2021","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"250","DOI":"10.5604\/01.3001.0010.8644","article-title":"More Evidence for the Genetic Susceptibility of Mexican Population to Nonalcoholic Fatty Liver Disease through PNPLA3","volume":"17","year":"2018","journal-title":"Ann. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14548","article-title":"Comparison of MAFLD and NAFLD Diagnostic Criteria in Real World","volume":"40","author":"Lin","year":"2020","journal-title":"Liver Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1111\/jgh.15156","article-title":"Global Epidemiology of Lean Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"35","author":"Lu","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.jhep.2021.07.035","article-title":"Metabolic Dysfunction-Associated Fatty Liver Disease Is Associated with Increased All-Cause Mortality in the United States","volume":"75","author":"Kim","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s12072-021-10147-0","article-title":"The Metabolic Profiles and Body Composition of Lean Metabolic Associated Fatty Liver Disease","volume":"15","author":"Cheng","year":"2021","journal-title":"Hepatol. Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/liv.14739","article-title":"The NAFLD-MAFLD Debate: Eminence vs. Evidence","volume":"41","author":"Fouad","year":"2021","journal-title":"Liver Int."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/19\/12221\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:40:09Z","timestamp":1760143209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/19\/12221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":23,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["ijerph191912221"],"URL":"https:\/\/doi.org\/10.3390\/ijerph191912221","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]}}}